Discover more from PharmaFiles by Aussie17
Part 1: Explosive dataset showing increase of turbo-cancer!
In the last two months, I had three family members diagnosed with cancer (thankfully, none have dropped dead suddenly). All of them are triple-jabbed with the Pfizer mRNA experiment.
It made me curious because I was expecting more cases of Myocarditis and cardiac-related issues to crop up. Still, from my direct personal social circles, it looks like the cancer is accelerating.
I decided to do a quick poll on Twitter asking folks what side effects they are seeing most among their social circle.
Some people commented that they saw no side effects and the poll was biased. Well, it wasn’t because all I wanted was to find out what was the most observed side effect. If I were to put “None observed”, probably 40%-50% of respondents would have seen nothing.
Maybe I should have grouped Myocarditis/Sudden Deaths; I didn’t think this through properly because I created this poll at the Speed of Science⟨™⟩, just like the experimental mRNA vaccine.
Three out of ten (from a sample of 3464) observed turbo cancer as the side effect that occurred the most among their direct social circles. It aligns with my observation.
As usual, I went looking for some hard data but data from the public domain came up with nothing. Governments worldwide are either fudging the data or delaying the release, which is getting annoying.
As you can see in the tweet from Jikkyleaks below, the Australian government are
hiding delaying diagnosis-related data.
I got curious, so I used my backdoor access to get some private Pharma sales data.
These are in-market sales data. I explained the various types of Sales data in this post. In-Market Sales data tells us the immediate demand for a drug.
Ex-factory Sales are just fudged-up numbers that show in Company Annual Reports.
vaccines experiment that governments are disposing of are Ex-Factory Sales. It doesn’t reflect actual accurate market demand because Big Pharma colludes with Governments to buy more drugs than the market truly needs - most of them get disposed of. For example, Europe bought ten doses of mRNA vaccines per citizen! (ha-ha!)
Here’s another example where the Singapore government blames USD100 million of expired COVID-19 vaccines as “insurance” (what the heck does that mean??). Again, it reeks of corruption or incompetence.
In-Market Sales data shows a more accurate demand for drugs because hospitals, clinics and pharmacies purchase them. Usually, they keep a fixed level of stock (for example, 30 days' worth of inventory), and they do some forecast to ensure stock levels stays stable. If a particular drug is used up faster than expected, they will purchase more in the next cycle.
Since governments are hell-bent on fudging/delaying diagnosis data, we can use in-market sales to examine what's happening in the market.
There are some caveats when looking at Sales data. For example:
If a particular drug loses its patent, generics will come in, and we will see the sales dive.
The drug may receive new indications - which will uplift sales. For example, the Auto-Immune drug Humira has more than ten different indications (rheumatoid arthritis, Crohn's disease, psoriasis, uveitis etc.
When a competitor launches a new product, it will affect sales.
There are many other sales dynamics, but you get the gist.
Diving into sales of some key cancer drugs!
Let’s look into the data! By the way, these are doses administered (I took off actual sales figure to avoid identification of data source)
Sales of JAKAVI (ruxolitinib).
Jakavi was launched in 2011 as the only approved oral medication for blood cancer myelofibrosis. In 2019 it received new indications in 2019, 2021 and December 2022. The 50% spike in sales during the 4th quarter of 2022 is notable. The new indication came on Dec 20, 2022, shouldn’t affect sales uplift by 50% from the prior quarter.
For a 12-year-old drug, it is surprising to see a sudden spike. I think there is a spike in new patients diagnosed with blood cancer. This country had 85% of their population triple jabbed by the end of 2021.
Myelofibrosis develops slowly - sometimes, it takes years before a patient experience any signs of symptoms. People with myelofibrosis usually complain of tiredness, weakness, and shortness of breath.
Sales of IBRANCE (palbociclib)
Ibrance (palbociclib) is a drug used to treat advanced or metastatic breast cancer launched in 2015. The last approval for a new indication for Ibrance occurred in April 2019. We can see that the sales have been relatively stable and only started to accelerate dramatically in the last two quarters.
Sales of Kisqali (ribociclib)
Kisqali (ribociclib) is a newer drug launched in 2017 for metastatic breast cancer. Because it’s a newer drug, sales started in 2018 and stabilised around 2020. It started accelerating again towards 2021 (sometimes, acceleration is due to further studies proving efficacy and not necessarily a new indication). Then, it went exponential (30%+ over the previous quarter) during the last quarter of 2022. There have been no new indications for Kisqali since 2018.
There is a surge in cancer rates, particularly in the last quarter of 2022, based on the evidence of in-market drug sales that I am looking at. I collated some cancer prevention strategies in this post.
I have A LOT more data available - I will look into more drugs in the coming days. Maybe Pfizer’s blood thinner Eliquis?
Please subscribe here if you would like to get notified.
If you are a medical professional and have some hypotheses on analysing the data further, please email me. I can only share with limited trusted/known sources to avoid trouble (these are private data sources).
Read Part 2 here:
Signing off for now
PS: I’m going through some bumps in real life, so my updates might take some time in the coming days and weeks.
Since I quit the Pharma industry 2+ years ago, I haven’t found a stable means of income and my savings are depleted. Right now, I’m looking for alternative sources of income. I want to keep this Substack free as long as possible because I think the fight is essential (and I’m not too fond of paywalls myself)
If you like to support my work, please consider donating a subscription! I’d appreciate it if you shared my posts, too; they are all free!
PharmaFiles by Aussie17 is a reader-supported publication. To receive new posts and support my work, consider becoming a free or paid subscriber.